Stockscreener 앱 받기
0.561
0.02%
0.0001
시간 외 거래:
.57
0.009
+1.60%
전일 마감가:
$0.5609
열려 있는:
$0.57
하루 거래량:
3.11M
Relative Volume:
0.40
시가총액:
$77.10M
수익:
-
순이익/손실:
$-12.89M
주가수익비율:
-0.2217
EPS:
-2.53
순현금흐름:
$-11.95M
1주 성능:
+3.18%
1개월 성능:
-13.69%
6개월 성능:
+89.27%
1년 성능:
-55.48%
1일 변동 폭
$0.542
$0.5799
1주일 범위
$0.4985
$0.58
52주 변동 폭
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
명칭
Plus Therapeutics Inc
전화
737.255.7194
주소
4200 MARATHON BLVD., AUSTIN, TX
PSTV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.561 | 77.08M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-03 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2025-03-17 | 개시 | D. Boral Capital | Buy |
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
| 2020-10-16 | 개시 | Maxim Group | Buy |
Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스
2026 world cup points table rankings: How Plus Therapeutics Inc. stock responds to policy changes2026 world cup usa national team round of 32 star players set piece tactics knockout prediction tactical review - Улправда
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Analyst Downgrade: How Plus Therapeutics Inc XMP0 stock expands through international marketsMarket Risk Summary & Accurate Intraday Trade Tips - moha.gov.vn
Guidance Update: Can Plus Therapeutics Inc XMP0 stock attract analyst upgradesJuly 2025 Setups & Safe Entry Momentum Tips - moha.gov.vn
How Plus Therapeutics Inc. stock reacts to job market dataEarnings Surprise Analysis & High Profit Trading Plans - bollywoodhelpline.com
Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
How Plus Therapeutics Inc. stock responds to policy changes2025 Market Overview & Safe Entry Momentum Tips - ulpravda.ru
Death Cross: How Plus Therapeutics Inc. stock reacts to job market data2025 Price Targets & Low Volatility Stock Recommendations - ulpravda.ru
Is Plus Therapeutics Inc. (XMP0) stock a top hedge fund pick2025 Momentum Check & Real-Time Stock Price Movement Reports - Улправда
Inflation Data: Can Plus Therapeutics Inc. stock continue upward trendTrade Performance Summary & Growth-Oriented Investment Plans - Улправда
Can Plus Therapeutics Inc. stock continue upward trendJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - Улправда
Can Plus Therapeutics Inc. (XMP0) stock ride next bull market cycleQuarterly Trade Summary & Weekly Breakout Stock Alerts - Улправда
Plus Therapeutics, Inc. (PSTV) Presents at 2025 San Antonio Breast Cancer Symposium (SABCS)Slideshow - Seeking Alpha
Plus Therapeutics (NASDAQ:PSTV) Earns "Buy" Rating from D. Boral Capital - MarketBeat
D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Analyst Jason Kolbert Maintains 'Buy' Rating for Plus Therapeuti - GuruFocus
CNSide Diagnostics expands lab licenses to three more states - Investing.com
Plus Therapeutics Expands CNSide Assay Platform to State of California - The Manila Times
Plus Therapeutics adds key personnel to CNSide Diagnostics team By Investing.com - Investing.com Canada
Plus Therapeutics (PSTV) Expands CNSide Diagnostics Team with Ke - GuruFocus
Plus Therapeutics adds key personnel to CNSide Diagnostics team - Investing.com
Plus Therapeutics Announces Key Hires to Strengthen Operations at CNSide Diagnostics, LLC - Quiver Quantitative
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants - The Manila Times
Why global investors buy Plus Therapeutics Inc. (XMP0) stockWeekly Investment Recap & Reliable Breakout Forecasts - Newser
Hines Adds 3 Life-Science Tenants at Levit Green - Realty News Report
Hines' Levit Green signs 3 biotech tenants for 30K-SF of lab and office space - The Business Journals
Plus Therapeutics Reports Positive Phase 1 Data for REYOBIQ in Leptomeningeal Metastases and Glioblastoma at WFNOS/SNO Annual Meeting | PSTV Stock News - Quiver Quantitative
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting - The Manila Times
Will Plus Therapeutics Inc. (XMP0) stock rise with strong economyTrade Ideas & Precise Buy Zone Tips - Newser
How Plus Therapeutics Inc. stock reacts to Fed rate cutsIPO Watch & Technical Entry and Exit Tips - Newser
Will Plus Therapeutics Inc. (XMP0) stock beat Nasdaq index returns2025 Analyst Calls & Smart Allocation Stock Reports - Newser
Plus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Aug Highlights: How Plus Therapeutics Inc. stock performs in weak economyMarket Sentiment Summary & Smart Allocation Stock Reports - BỘ NỘI VỤ
Will Plus Therapeutics Inc. stock gain from lower inflationTrade Signal Summary & High Accuracy Trade Alerts - Newser
How higher bond yields impact Plus Therapeutics Inc. (XMP0) stock2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - Newser
How dovish Fed policy supports Plus Therapeutics Inc. (XMP0) stock2025 Price Action Summary & Risk Controlled Daily Trade Plans - Newser
Plus Therapeutics granted 180-day to regain compliance with Nasdaq - MSN
Why Plus Therapeutics Inc. stock is favored by top institutions - Newser
Plus Therapeutics (PSTV) Analyst Rating Update: Maintain Buy Rat - GuruFocus
Plus Therapeutics to present breast cancer treatment data at SABCS By Investing.com - Investing.com Nigeria
Plus Therapeutics to present breast cancer treatment data at SABCS - Investing.com
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium - The Manila Times
Plus Therapeutics, Inc. Announces Abstract Acceptance for Spotlight Presentation at San Antonio Breast Cancer Symposium 2025 on Rhenium (186Re) obisbemeda for Leptomeningeal Metastases Treatment - Quiver Quantitative
Plus Therapeutics (NASDAQ: PSTV) lands SABCS 2025 spotlight for LM Phase 1 trial - Stock Titan
HC Wainwright Expects Weaker Earnings for Plus Therapeutics - MarketBeat
Plus Therapeutics Inc (PSTV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):